Akums Drugs & Pharmaceuticals Share Price

    425.3
    +5.80 (1.38%)
    AKUMS • 28 Nov, 2025 | 02:49 PM
    Buy
    with MTF at2.86xleverage
    The current prices are delayed, login or Open Demat Account for live prices.

    Akums Drugs & Pharmaceuticals Stock Performance

    1W Return0.87
    1Y Return-29.97
    Today's Low417.75
    Prev. Close419.50
    Mkt Cap (Cr.)6,602.68
    1M Return-6.98
    3Y Return0.00
    52-Week High678.4
    Open421.95
    PE Ratio48.10
    6M Return-26.22
    Today's High432
    52-Week Low405
    Face Value2

    Akums Drugs & Pharmaceuticals Company background

    Founded in: 2004
    Managing director: SANDEEP JAIN
    Akums Drugs and Pharmaceuticals Limited was incorporated vide Certificate of Incorporation dated April 19, 2004 and received a Certificate for Commencement of Business dated May 13, 2004 issued by the RoC.Alkums Drugs Pharmas are a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. They are into sale of branded pharmaceutical formulations and manufacturing of Active Pharmaceutical Ingredients. Some of the other services include formulation research and development, preparation and filing of regulatory dossiers into the Indian and global markets, and other testing services. Some of manufacturing units have been accredited by various global regulatory agencies such as the European Good Manufacturing Practice, the World Health Organization Good Manufacturing Practice and the United States National Sanitation Foundation. Their specialization extends to development and sale of APIs across diverse chemical processes and therapeutic areas such as antiinfective, respiratory and diabetes. In 2004, the Company established first plant for oral dosage commissioned at 19, 20, 21, Sector 6A, Haridwar, Uttarakhand. In 2007, it established dedicated manufacturing site for oral liquid dosage and sterile products both at Haridwar, Uttarakhand. It incorporated Maxcure Nutravedics Limited to venture into nutraceuticals in 2009. In 2010, it dedicated a facility for hormones dedicated a facility for cosmetics and dermatology at Haridwar, Uttarakhand. In 2010, it incorporated Akumentis Healthcare Limited to venture into branded formulations.In 2011, it innovated bilayered sustained release tablets for the first time. In 2012, acquired subsidiary, Pure and Cure Healthcare Private Limited to expand capacity and capabilities. In 2013, it acquired Malik Lifesciences Private Limited manufacturing sites to expand capacity and capabilities. It established RD Laboratory in Mumbai, Maharashtra to venture into regulated market in 2015. In 2021, the Company acquired Parabolic Drugs to form Akums Lifesciences Limited and ventured into APIs. Further, it acquired Kotdwar Plant in Uttarakhand by Akums Healthcare Limited. In 2022, it acquired facility in Haridwar, Uttarakhand through the subsidiaries, Akums Healthcare Limited and in 2023, acquired Baddi facility in, Himachal Pradesh through Pure and Cure Healthcare Private LimitedFollowing a Scheme of Arrangement on October 17, 2023, Akums Lifesciences Limited got merged with its subsidiary, Pure and Cure Healthcare Private Limited (PCHL) with effect from April 1, 2022. As part of this acquisition, it acquired manufacturing units in Dera Bassi and Lalru in Punjab and Barwala in Haryana, and an RD centre in Barwala, Haryana and commenced operations in the manufacture and sale of key starting materials, intermediates and APIs. The Company launched an IPO by issuing 27,368,151 equity shares of Rs 2 each by raising funds aggregating to Rs 1857 Crore comprising a fresh issue of 10,037,716 equity shares aggregating to Rs 680 Crore and offer for sale of 17,330,435 equity shares aggregating to Rs 1177 Crore in August, 2024.Akums Healthcare UK Ltd. was incorporated as a foreign wholly owned subsidiary of the Company on 18th March, 2025. The new stateoftheart facilities at Kotdwar and Haridwar, focusing on Penem anti infectives and general injectables, have enhanced the manufacturing capacity in FY 2025.

    Akums Drugs & Pharmaceuticals Financial Highlights


    Akums Drugs & Pharmaceuticals reported a Q2 FY 2025-26 revenue of ₹1017.53 crore, down -1.0% YoY, with net profit increased 43416.5% to ₹42.7 crore. For the full year FY2025–2026, revenue reached ₹4170.28 crore and profit touched at ₹343.78 crore. As of Sep '25, Akums Drugs & Pharmaceuticals’s market capitalisation stood at ₹6,602.68 crores. Shareholding as of Sep '25 shows promoters holding 75.3%, with FIIs at 2.3%, DIIs at 9.3%, and public at 10.5%.

    Akums Drugs & Pharmaceuticals Share Price Today


    As of 28 Nov 2025, Akums Drugs & Pharmaceuticals share price is ₹424.8. The stock opened at ₹422 and had closed at ₹419.5 the previous day. During today’s trading session, Akums Drugs & Pharmaceuticals share price moved between ₹417.75 and ₹432.00, with an average price for the day of ₹424.88. Over the last 52 weeks, the stock has recorded a low of ₹405.00 and a high of ₹678.40. In terms of performance, Akums Drugs & Pharmaceuticals share price has declined by 26.4% over the past six months and has declined by 46% over the last year.
    Read More
    View details of Market Depth

    Akums Drugs & Pharmaceuticals Fundamental

    Market Cap (in crs)

    6,602.68

    Face Value

    2

    Turnover (in lacs)

    574.49

    Key Metrics

    Qtr Change %
    Near 52W Low of ₹405.00
    -11
    Dividend yield 1yr %
    0

    Akums Drugs & Pharmaceuticals Key Financials

    View more
    Loading chart...
    Loading chart...
    Loading chart...
    Loading chart...
    Akums Drugs & Pharmaceuticals Quarterly Revenue
    Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
    1017.53 Cr
    1024.03 Cr
    1055.55 Cr
    1010.41 Cr
    1033.09 Cr
    Akums Drugs & Pharmaceuticals Yearly Revenue
    Mar 2025Mar 2024Mar 2023Mar 2022
    4170.28 Cr
    4212.21 Cr
    3700.92 Cr
    3694.52 Cr
    Akums Drugs & Pharmaceuticals Quarterly Net Profit/Loss
    Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
    42.7 Cr
    64.68 Cr
    149.61 Cr
    66.31 Cr
    66.65 Cr
    Akums Drugs & Pharmaceuticals Yearly Net Profit/Loss
    Mar 2025Mar 2024Mar 2023Mar 2022
    343.78 Cr
    0.79 Cr
    98.02 Cr
    -251.08 Cr

    Akums Drugs & Pharmaceuticals Result Highlights

    • Akums Drugs & Pharmaceuticals Ltd reported a 0.1% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 0.3%.

    • Its expenses for the quarter were up by 3.0% QoQ and 2.7% YoY.

    • The net profit decreased 34.0% QoQ and decreased 35.9% YoY.

    • The earnings per share (EPS) of Akums Drugs & Pharmaceuticals Ltd stood at 2.66 during Q2 FY 2025-26.

      Read more

    Data Source: BSE, Company announcements

    The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

    Akums Drugs & Pharmaceuticals Shareholding Pattern

    Promoter
    75.3%
    Foreign Institutions
    2.3%
    Mutual Funds
    6.4%
    Domestic Institutions
    9.3%
    Public
    10.5%
    Promoter
    75.3%
    Foreign Institutions
    4.2%
    Mutual Funds
    6.7%
    Domestic Institutions
    8.9%
    Public
    8.9%
    Promoter
    75.3%
    Foreign Institutions
    5.8%
    Mutual Funds
    6.1%
    Domestic Institutions
    7.4%
    Public
    8.8%
    Promoter
    75.3%
    Foreign Institutions
    6.4%
    Mutual Funds
    5.5%
    Domestic Institutions
    7%
    Public
    8.6%
    Promoter
    75.3%
    Foreign Institutions
    7.3%
    Mutual Funds
    5.2%
    Domestic Institutions
    7.6%
    Public
    7.1%

    Akums Drugs & Pharmaceuticals Technical Analysis

    Moving Averages Analysis
    425.3
    Current Price
    Bullish Moving Averages
    3
    Bearish Moving Averages
    13
    Day EMA5
    422.60
    Day EMA10
    426.80
    Day EMA12
    428.70
    Day EMA20
    435.30
    Day EMA26
    439.10
    Day EMA50
    451.40
    Day EMA100
    474.60
    Day EMA200
    531.60
    Day SMA5
    421.20
    Day SMA10
    424.70
    Day SMA20
    439.80
    Day SMA30
    447.80
    Day SMA50
    451.30
    Day SMA100
    478.60
    Day SMA150
    503.20
    Day SMA200
    501.60
    Delivery & Volume
    Loading chart...

    Delivery & Volume

    PeriodCombined Delivery VolumeNSE+BSE Traded Volume
    Day Rs
    58896 Rs
    109623 Rs
    Week Rs
    178437 Rs
    297933 Rs
    Month Rs
    137096 Rs
    248111 Rs
    422.17
    Pivot
    Resistance
    First Resistance
    427.33
    Second Resistance
    435.17
    Third Resistance
    440.33
    Support
    First Support
    414.33
    Second support
    409.17
    Third Support
    401.33
    Relative Strength Index
    38.90
    Money Flow Index
    27.04
    MACD
    -10.41
    MACD Signal
    -8.95
    Average True Range
    13.60
    Average Directional Index
    15.94
    Rate of Change (21)
    -8.25
    Rate of Change (125)
    -26.55

    Name
    Holding Percent
    Franklin India Opportunites Fund
    4.18
    Clarus Capital I
    1.3

    Akums Drugs & Pharmaceuticals Latest News

    17 NOV 2025 | Monday

    Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    17 NOV 2025 | Monday

    Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    14 NOV 2025 | Friday

    Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

    View More

    Akums Drugs & Pharmaceuticals Share Price FAQs

    Akums Drugs & Pharmaceuticals share price is ₹425.3 in NSE and ₹425.5 in BSE as on 28/11/2025.

    Akums Drugs & Pharmaceuticals share price in the past 1-year return was -29.96. The Akums Drugs & Pharmaceuticals share hit a 1-year low of Rs. 405 and a 1-year high of Rs. 678.4.

    The market cap of Akums Drugs & Pharmaceuticals is Rs. 6602.68 Cr. as of 28/11/2025.

    The PE ratios of Akums Drugs & Pharmaceuticals is 48.1 as of 28/11/2025.

    The PB ratios of Akums Drugs & Pharmaceuticals is 2.77 as of 28/11/2025

    The Mutual Fund Shareholding in Akums Drugs & Pharmaceuticals was 6.44% at the end of 28/11/2025.

    You can easily buy Akums Drugs & Pharmaceuticals shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

    The 52-week high and low of Akums Drugs & Pharmaceuticals share price is ₹678.4 and ₹405 as of 28/11/2025.

    The earnings per share (EPS) of Akums Drugs & Pharmaceuticals stood at 2.66 during Q2 FY 2025-26.

    Please be aware that Akums Drugs & Pharmaceuticals stock prices are subject to continuous fluctuations due to various factors.

    Invest in Akums Drugs & Pharmaceuticals
    +91 -

    Popular Stocks
    323.00
    -1.55 (-0.48%)
    167.88
    -0.25 (-0.15%)
    300.15
    -2.60 (-0.86%)
    409.55
    -3.50 (-0.85%)
    389.90
    -2.15 (-0.55%)
    Top Gainers
    3,755.60
    +74.40 (+2.02%)
    2,282.20
    +27.20 (+1.21%)
    1,831.90
    +21.60 (+1.19%)
    982.00
    +9.15 (+0.94%)
    1,258.20
    +8.90 (+0.71%)
    Top Losers
    1,968.20
    -36.30 (-1.81%)
    852.25
    -15.40 (-1.77%)
    764.45
    -13.35 (-1.72%)
    270.00
    -3.70 (-1.35%)
    300.00
    -2.75 (-0.91%)
    Invest in Akums Drugs & Pharmaceuticals
    +91 -